BofA analyst Tim Anderson raised the firm’s price target on Amgen (AMGN) to $261 from $252 and keeps an Underperform rating on the shares. For Q2, the firm’s revenue and underlying EPS estimates are raised 3% and 5%, respectively, due to a positive forex adjustment and taking into account script trends for certain key products. For 2025 and 2026, total revenue estimates are higher by 2%-3% while EPS is up by 2%-4%, the analyst tells investors in a preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Overvaluation and Cautious Outlook Lead to Underperform Rating
- Amgen’s Blinatumomab Study: A Potential Game-Changer for Leukemia Treatment
- Amgen price target raised to $305 from $300 at Citi
- Amgen’s Promising Study on Advanced Gastric Cancer: What Investors Need to Know
- Amgen price target raised to $326 from $315 at UBS